Filter results

Opiod-Related Disorders clinical trials

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

View clinical trials related to Opiod-Related Disorders.

Filter by:

None
Page 1

NCT ID: NCT02225184 Completed - Clinical trials for Drug Abuse/Dependence

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

Start date: August 23, 2014
Phase:
Study type: Observational

Background: - Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Americans with a certain genetic marker did better using one kind of drug treatment over the other. Researchers want to see if they can repeat these findings. They also want to study other things that affect how well people do in treatment. Objective: - To see if certain genetic markers and other facts about a person s life can predict how well they do in treatment for addiction to opioids and cocaine. Eligibility: - African American adults age 18 and over. They must be former or current participants in an Archway Treatment Clinic study. They must have been on a stable dose of either study drug for at least 12 weeks. They also must have given urine samples regularly for at least 10 weeks. Design: - Participants will come to the clinic for 1 visit lasting about 2 hours. - Participants will give 1 teaspoon of blood for genetic testing. They will be asked if their sample can be used in future studies. - If researchers cannot get enough blood, they will do a cheek swab. This will collect skin cells for genetic testing. - Participants will fill out 3 questionnaires. - Results of genetic testing and answers to questionnaires will be kept private.